




RealRate

# PHARMACEUTICAL 2019

Evoke Pharma Inc  
Rank 257 of 361



The relative strengths and weaknesses of Evoke Pharma Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Evoke Pharma Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 32% points. The greatest weakness of Evoke Pharma Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 91% points.

The company's Economic Capital Ratio, given in the ranking table, is 173%, being 77% points below the market average of 250%.

| Input Variable                              | Value in 1000 USD |
|---------------------------------------------|-------------------|
| Assets, Current                             | 5,648             |
| Cost of Goods Sold                          | 0                 |
| Intangible Assets                           | 0                 |
| Liabilities, Current                        | 1,634             |
| Liabilities, Non-Current                    | 0                 |
| Other Assets                                | 12                |
| Other Compr. Net Income                     | 0                 |
| Other Expenses                              | 0                 |
| Other Liabilities                           | 0                 |
| Other Net Income                            | 449               |
| Other Revenues                              | 0                 |
| Property and Equipment                      | 0                 |
| Research and Development                    | 4,095             |
| Selling, General and Administrative Expense | 3,920             |

| Output Variable              | Value in 1000 USD |
|------------------------------|-------------------|
| Assets                       | 5,660             |
| Liabilities                  | 1,634             |
| Expenses                     | 8,015             |
| Revenues                     | 0                 |
| Stockholders Equity          | 4,025             |
| Net Income                   | -7,566            |
| Comprehensive Net Income     | -7,566            |
| BaseVar                      | 7,879             |
| ECR before Limited Liability | 33%               |
| Economic Capital Ratio       | 173%              |